Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

TRACON Pharmaceuticals Inc. (TCON)

2.5   -0.28 (-10.07%) 12-12 16:00
Open: 2.76 Pre. Close: 2.78
High: 3.1769 Low: 2.5
Volume: 26,347 Market Cap: 8M
TRACON Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.184 - 3.2 3.2 - 3.215
Low: 2.463 - 2.479 2.479 - 2.494
Close: 2.471 - 2.496 2.496 - 2.52

Technical analysis

as of: 2019-12-12 4:35:03 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.15     One year: 4.91
Support: Support1: 2.50    Support2: 2.08
Resistance: Resistance1: 3.55    Resistance2: 4.20
Pivot: 3.20
Moving Average: MA(5): 2.81     MA(20): 3.22
MA(100): 4.16     MA(250): 6.99
MACD: MACD(12,26): -0.24     Signal(9): -0.16
Stochastic oscillator: %K(14,3): 1.96     %D(3): 6.99
RSI: RSI(14): 32.77
52-week: High: 17.30  Low: 2.50  Change(%): -75.7
Average Vol(K): 3-Month: 2827  10-Days: 2810

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
TCON has closed below the lower band by 2.9%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

TRACON Pharmaceuticals (NASDAQ:TCON) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
TRACON Pharmaceuticals (NASDAQ:TCON) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.03, Fidelity Earnings reports. NASDAQ TCON traded down $0.02 during trading hours on Thursday, reaching $0.40. The company had a trading volume of 368 shares, compared to […]

Tracon Pharma Shares Rally As First Patient Dosed In Cancer Trial
Shares of the thinly traded nanocap biotech TRACON Pharmaceuticals Inc (NASDAQ: TCON ) were rallying Thursday. What Happened Tracon, which specializes in novel therapeutics for cancer, said it has dosed the first patient in a U.S. Phase 1 first-in-human clinical trial of I-Mab's proprietary CD73 antibody TJD5, also known as TJ004309, in patients with advanced solid tumors. TJD5 is from Chinese biopharma stable and it is being co-developed through a corporate collaboration between Tracon and I-Mab that was signed in November 2018. TJD5 will be dosed in the Phase 1 trial both as a single agent … Full story available on

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 3.14
Shares Float (M) 1.69
% Held by Insiders 8.89
% Held by Institutions 67.23
Shares Short (K) 59
Shares Short P. Month (K)

Stock Financials

EPS -8.857
Book Value (p.s.) 1.350
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -47.0
Return on Equity (ttm) -162.6
Qtrly Rev. Growth
Gross Profit (p.s.) -6.653
Sales Per Share
EBITDA (p.s.) -8.341
Qtrly Earnings Growth
Operating Cash Flow (M) -27.53
Levered Free Cash Flow (M) -17.75

Stock Valuations

P/E -0.28
P/E Growth Ratio -0.10
P/BV 1.85
P/CF -0.29

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2019-11-08
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.